Lilly Invests In MiNA To Fund Protein-Upregulating RNA Programs

by Vandana Singh, Benzinga Editor

July 6, 2021 11:06 AM | 1 min read | Make a Comment

Eli Lilly And Co LLY is set to invest $15 million in its small activating RNA (saRNA) partner, MiNA Therapeutics.
The investment comes two months after Lilly agreed to pay $25 million upfront to work with MiNA on up to five targets.
MiNA will use the money to advance its internal pipeline of saRNA therapeutics, led by a drug designed to cut immunosuppression by raising levels of the C/EBP-⍺ master regulator of myeloid cell differentiation.
Price Action: LLY shares are up 0.05% at $234.07 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Financing Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.